TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31282704

Group type: EXPERIMENTAL
Intervention: 0.65g/kg alcohol
Number of subjects: 40
Study: 30368541

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 28514945

Group type: EXPERIMENTAL
Intervention: Preoperative work-up with addition of the prediction model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard preoperative work-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient reported outcomes measured by BREAST-Q, EORTC-QLQ-C30/BR23 and EQ-5D-5L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cosmetic outcome assessed through BCCT.core software
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation-induced reaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment performed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathological result
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 0
Study: 26347153

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 84496
Study: 23478662

Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg, 3 times daily for 12 weeks, followed by 60 mg, 3 times daily for 12 weeks)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 216
Study: 21186062

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17
Study: 18315784

Group type: EXPERIMENTAL
Intervention: DTIC (2200 mg/kg orally daily for 5 days, every 3 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DTIC + CCNU (DTIC at 2200 mg/kg and CCNU at 120 mg/m2 once every 40 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control healthy volunteers
Number of subjects: 21
Study: 17023870

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate 1.25 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate 2.5 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate 5.0 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate 7.5 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Increasing dose of methylphenidate
Number of subjects: 81
Study: 12877375

Group type: EXPERIMENTAL
Intervention: Structured oncology information pack
Number of subjects: 248

Group type: COMPARATOR
Intervention: Traditional information provided by the department
Number of subjects: 248
Study: 11133707

Group type: EXPERIMENTAL
Intervention: ECCE (extracapsular cataract extraction)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nucleus capture
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 108
Study: 9722817

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) with free treatment for 90 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Motivational interviewing (MI) without free treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Risk reduction (RR) with free treatment for 90 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Risk reduction (RR) without free treatment
Number of subjects: 200
Study: 7987510

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan, 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous sumatriptan, 6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined subcutaneous and oral administration of sumatriptan
Number of subjects: 0
Study: 2498956

Group type: EXPERIMENTAL
Intervention: 24 hours of smokeless tobacco deprivation
Number of subjects: 40

Group type: COMPARATOR
Intervention: No deprivation (control group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonchewers (third control group)
Number of subjects: 40
Study: 1094787

Group type: EXPERIMENTAL
Intervention: Nylidrin hydrochloride
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Isoxuprine hydrochloride
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194

Group type: COMPARATOR
Intervention: Ethyl alcohol
Number of subjects: 194
Study: 31340565

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% + 100 mg Tramadol (2 mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine 0.5% + 2 mL NaCl 0.9% (placebo)
Number of subjects: 80
Study: 26443696

Group type: EXPERIMENTAL
Intervention: Low-intensity strength training at 20% of 1RM combined with partial blood flow restriction (LI + BFR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-intensity strength training at 80% of 1RM (HI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-intensity strength training at 20% of 1RM (LI)
Number of subjects: 40
Study: 25142277

Group type: EXPERIMENTAL
Intervention: Balance training program including dual‐ and multi‐task exercises, three times/week for 12 weeks.
Number of subjects: 96
Study: 23239300

Group type: EXPERIMENTAL
Intervention: One-step procedure (laparoscopic cholecystectomy with intraoperative cholangiogram and ERCP if necessary)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two-step procedure (preoperative ERCP followed by laparoscopic cholecystectomy)
Number of subjects: 20
Study: 21205128

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg and 1.8 mg
Number of subjects: 0
Study: 18461664

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (Healive); 1 dose administered to 108 individuals and 3365 students.
Number of subjects: 4675

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (Healive); 1 dose administered to 3365 students.
Number of subjects: 4675

Group type: COMPARATOR
Intervention: Control group (no vaccination); 115 individuals and 2572 students.
Number of subjects: 4675
Study: 16467770

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study: 12975572

Group type: EXPERIMENTAL
Intervention: Dual chamber electrograms (both atrial and ventricular)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ventricular electrograms alone
Number of subjects: 52
Study: 12135299

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 IU) administered preoperatively, with 2 or 3 doses depending on the procedure, along with oral iron for 14 or 21 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched historical control patients receiving standard care without epoetin alfa.
Number of subjects: 0
Study: 9375348

Group type: EXPERIMENTAL
Intervention: Sequential exercise day (SEB; at 1000, 1130, and 1300)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Delayed exercise day (DEB; at 1000, 1400, and 1800)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Delayed exercise day (DEB)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sequential exercise day (SEB)
Number of subjects: 7
Study: 7902470

Group type: EXPERIMENTAL
Intervention: H2-blockers (Histadyl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term maintenance therapy with drugs improving local microcirculation and stimulating bicarbonates production in gastric mucosa (synthetic prostaglandins analogues)
Number of subjects: 0
Study: 30335135

Group type: EXPERIMENTAL
Intervention: Rotavac vaccine (monovalent human-bovine 116E)
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Presence of coinfections
Number of subjects: 1169
Study: 29617381

Group type: EXPERIMENTAL
Intervention: 8g PEG-3350
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 17g PEG-3350
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: PEG treatment (both doses combined)
Number of subjects: 87
Study: 26794725

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computed tomography
Number of subjects: 0
Study: 25208561

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich dark chocolate (50 g)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo chocolate (50 g)
Number of subjects: 65
Study: 21811866

Group type: EXPERIMENTAL
Intervention: Monthly ibandronate treatment for 12 months
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo treatment for 12 months
Number of subjects: 89
Study: 20633818

Group type: EXPERIMENTAL
Intervention: SXscore<or=8 (SXlow) (n=464)
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: SXscore>8 and <or=16 (SXmid) (n=472)
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: SXscore>16 (SXhigh) (n=461)
Number of subjects: 1397

Group type: COMPARATOR
Intervention: SXscore<or=8 (SXlow)
Number of subjects: 1397

Group type: COMPARATOR
Intervention: SXscore>8 and <or=16 (SXmid)
Number of subjects: 1397

Group type: COMPARATOR
Intervention: SXscore>16 (SXhigh)
Number of subjects: 1397
Study: 16911813

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 200 mg/day
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combination of Orlistat and Fenofibrate
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 89
Study: 15951101

Group type: EXPERIMENTAL
Intervention: 100 microg oral misoprostol every 4 h
Number of subjects: 99

Group type: COMPARATOR
Intervention: 50 microg vaginal misoprostol every 4 h
Number of subjects: 99
Study: 12030962

Group type: EXPERIMENTAL
Intervention: Alverine citrate (120 mg capsule, three times daily for 12 weeks)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Alverine citrate
Number of subjects: 107
Study: 10081543

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laryngeal mask insertion
Number of subjects: 20
Study: 7741779

Group type: EXPERIMENTAL
Intervention: Mexiletine-ratiopharm mite (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial reference preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 0
Study: 1791021

Group type: EXPERIMENTAL
Intervention: Bidi smokers
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mixed smokers
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Symptomatic cigarette smokers
Number of subjects: 125

Group type: COMPARATOR
Intervention: Healthy non-smokers (control)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: All smokers
Number of subjects: 125
Study: 7050907

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regional heparinisation
Number of subjects: 10
Study: 31779479

Group type: EXPERIMENTAL
Intervention: At-Home urine collection methodology
Number of subjects: 0
Study: 30566590

Group type: EXPERIMENTAL
Intervention: Nivolumab plus SOX
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nivolumab plus CapeOX
Number of subjects: 40
Study: 25892165

Group type: EXPERIMENTAL
Intervention: Instructor-led training (ILT)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Online training (OLT)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Treatment manual (TM)
Number of subjects: 172

Group type: COMPARATOR
Intervention: All conditions (ILT, OLT, TM)
Number of subjects: 172
Study: 23795737

Group type: EXPERIMENTAL
Intervention: Acetazolamide (125 mg bid)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Gingko biloba (120 mg bid)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 20153154

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 200mg red yeast rice extract and 10mg policosanols once-daily for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 40
Study: 19624076

Group type: EXPERIMENTAL
Intervention: Viabahn polytetrafluoroethylene-covered stent-grafts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-expanding bare nitinol stents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent without a polymer coating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balloons coated with paclitaxel
Number of subjects: 0
Study: 17704425

Group type: EXPERIMENTAL
Intervention: CRT‐IA (150 mg/m², four courses) with sodium thiosulfate
Number of subjects: 158

Group type: COMPARATOR
Intervention: CRT‐IV (100 mg/m², three courses) without sodium thiosulfate
Number of subjects: 158
Study: 15073851

Group type: COMPARATOR
Intervention: Carboplatin and Paclitaxel (CP) - Paclitaxel at a dose of 225 mg/m² and carboplatin (AUC of 6) every 21 days
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) - standard dosage
Number of subjects: 85

Group type: COMPARATOR
Intervention: Comparison of toxicities
Number of subjects: 85

Group type: COMPARATOR
Intervention: Quality of life assessment using FACT-BL
Number of subjects: 85
Study: 11560562

Group type: EXPERIMENTAL
Intervention: Abciximab (ABC) with ASA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tirofiban (T) with ASA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) with ABC and ASA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) with T and ASA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (reviparin, REV) with ABC and ASA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (reviparin, REV) with T and ASA
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo with ABC and ASA
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo with T and ASA
Number of subjects: 18
Study: 9460232

Group type: EXPERIMENTAL
Intervention: Exposure to 160 micrograms/m3 for 60 min
Number of subjects: 9

Group type: COMPARATOR
Intervention: Exposure to 40 micrograms/m3 for 60 min
Number of subjects: 9
Study: 8179144

Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rigid laryngoscopic intubation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study: 3259002

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12
Study: 31710593

Group type: EXPERIMENTAL
Intervention: Abdominal massage (15-min twice a day for 3 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine cares (control group)
Number of subjects: 70
Study: 30987668

Group type: EXPERIMENTAL
Intervention: EPA and DHA supplementation (600 mg EPA and 260 mg DHA per day for 8 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 16
Study: 28389552

Group type: EXPERIMENTAL
Intervention: 8 mg/kg TCZ + MTX
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 1157

Group type: COMPARATOR
Intervention: 4 mg/kg TCZ + MTX
Number of subjects: 1157
Study: 25644503

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Blank Control
Number of subjects: 24
Study: 23606811

Group type: EXPERIMENTAL
Intervention: Lateral decubitus position group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supine position group
Number of subjects: 120
Study: 21423068

Group type: EXPERIMENTAL
Intervention: Single session of panretinal photocoagulation using pattern scan laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multiple sessions of conventional laser
Number of subjects: 50
Study: 19785727

Group type: EXPERIMENTAL
Intervention: Financial incentive for each anti-psychotic depot medication received over a 12 month period
Number of subjects: 136

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 136
Study: 17010227

Group type: EXPERIMENTAL
Intervention: Formula with nucleotides (NT+; n 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Formula without nucleotides (NT-; n 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nutritional recovery
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Age and nutritional recovery
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All variables included
Number of subjects: 26
Study: 15554359

Group type: EXPERIMENTAL
Intervention: Synthetic peptide corresponding to residues 34-39 in TSHR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiserum to the synthetic peptide corresponding to residues 34-39 in TSHR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alphal-antitrypsin
Number of subjects: 0
Study: 11499801

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 41

Group type: COMPARATOR
Intervention: Inhibitor titer < 2.0 U/mL
Number of subjects: 41

Group type: COMPARATOR
Intervention: Inhibitor titer >= 2.0 U/mL
Number of subjects: 41

Group type: COMPARATOR
Intervention: Neurological abnormalities
Number of subjects: 41
Study: 9230853

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 50
Study: 8501085

Group type: EXPERIMENTAL
Intervention: Use of a tourniquet (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No tourniquet (Group 2)
Number of subjects: 80
Study: 3656551

Group type: EXPERIMENTAL
Intervention: Silicone catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teflon-coated catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latex catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silicone-coated catheters
Number of subjects: 0
Study: 31542384

Group type: EXPERIMENTAL
Intervention: Levoketoconazole, starting at 150 mg twice daily, titrated up to a maximum of 600 mg twice daily during a 2-21 week dose-titration phase followed by a 6-month maintenance phase.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Levoketoconazole treatment
Number of subjects: 94
Study: 27506909

Group type: EXPERIMENTAL
Intervention: Positive habitual expectations
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Manipulated expectations (multimedia presentations suggesting different health benefits)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Exercise (moderate 30 min cycling)
Number of subjects: 76
Study: 26464000

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of dexmedetomidine (DEX) 0.8 μg · kg‐1 · min‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study: 24888284

Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30
Study: 22760426

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 19388120

Group type: EXPERIMENTAL
Intervention: Gadolinium doped saline flush (50 mM gadolinium, total Gd: 0.11 mmol/kg, flow-rate: 2 mL/s)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pure saline flush (0.9% saline solution)
Number of subjects: 22
Study: 18086963

Group type: EXPERIMENTAL
Intervention: TORS radical tonsillectomy
Number of subjects: 27
Study: 14983408

Group type: EXPERIMENTAL
Intervention: Metformin + recombinant human growth hormone (rhGH) (daily dose 9.5 microg/kg body weight)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Metformin + Placebo
Number of subjects: 25
Study: 12483466

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day for 6 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 10450619

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) led by professional therapists
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) led by paraprofessional therapists
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Mutual Support Group Therapy (MSG) led by professional therapists
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Mutual Support Group Therapy (MSG) led by paraprofessional therapists
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 98
Study: 7570730

Group type: EXPERIMENTAL
Intervention: Oral glucose (1 g/kg body wt)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral xylose (0.83 g/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tilt (60 degrees)
Number of subjects: 17
Study: 2695156

Group type: EXPERIMENTAL
Intervention: Paracervical lignocaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 70
Study: 732296

Group type: EXPERIMENTAL
Intervention: 4 pollen extract capsules
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 4 protein extract capsules
Number of subjects: 18

Group type: COMPARATOR
Intervention: 4 placebo capsules
Number of subjects: 18
Study: 30898111

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy (28 sessions)
Number of subjects: 8
Study: 28895143

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasonography (LUS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Laparoscopy alone (Control)
Number of subjects: 300
Study: 25697911

Group type: EXPERIMENTAL
Intervention: Attentional retraining
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 118
Study: 24821974

Group type: EXPERIMENTAL
Intervention: Newspaper articles (9 groups assigned to different articles)
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Excerpt of the official Association of Clinical Cancer Centers web pages (1 group)
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 1950
Study: 22027860

Group type: EXPERIMENTAL
Intervention: 12-week medicine ball training program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Regular training
Number of subjects: 21